Is Glucose-6-Phosphate Dehydrogenase Deficiency a Risk Factor for Autoimmune Thyroid Disease? A Retrospective Case-Control Study.
autoimmune thyroid disease
glucose-6-phosphate dehydrogenase deficiency
oxidative stress
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
03 02 2023
03 02 2023
Historique:
received:
31
12
2022
revised:
25
01
2023
accepted:
01
02
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
15
2
2023
Statut:
epublish
Résumé
The risk of developing thyroid disorders (TDs) in subjects with inherited glucose-6-phosphate dehydrogenase (G6PD) deficiency is unknown. The aim of this study was to explore the association between autoimmune (AITD) and G6PD deficiency in Northern Sardinia, in a population with a high frequency of these two conditions. In this retrospective single-center case-control study, demographic and clinical data were collected from patients examined in a tertiary referral Gastroenterology Section of a teaching hospital. In 8894 subjects examined (64.7% females), 1218 patients were diagnosed with TDs; more specifically, 767 were diagnosed with AITD and 451 were not (non-AITD). Overall, G6PD deficiency was more prevalent in TD patients compared with patients without TD (controls) (16.7% vs. 11.2%; The risk of AITD is increased in carriers of G6PD deficiency. A careful assessment of thyroid function is advisable in patients with inherited G6PD defects.
Sections du résumé
BACKGROUND
The risk of developing thyroid disorders (TDs) in subjects with inherited glucose-6-phosphate dehydrogenase (G6PD) deficiency is unknown. The aim of this study was to explore the association between autoimmune (AITD) and G6PD deficiency in Northern Sardinia, in a population with a high frequency of these two conditions.
METHODS
In this retrospective single-center case-control study, demographic and clinical data were collected from patients examined in a tertiary referral Gastroenterology Section of a teaching hospital.
RESULTS
In 8894 subjects examined (64.7% females), 1218 patients were diagnosed with TDs; more specifically, 767 were diagnosed with AITD and 451 were not (non-AITD). Overall, G6PD deficiency was more prevalent in TD patients compared with patients without TD (controls) (16.7% vs. 11.2%;
CONCLUSIONS
The risk of AITD is increased in carriers of G6PD deficiency. A careful assessment of thyroid function is advisable in patients with inherited G6PD defects.
Identifiants
pubmed: 36768075
pii: ijerph20032709
doi: 10.3390/ijerph20032709
pmc: PMC9916078
pii:
doi:
Substances chimiques
Glucosephosphate Dehydrogenase
EC 1.1.1.49
G6PD protein, human
EC 1.1.1.49
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Int J Toxicol. 2001 Jan-Feb;20(1):15-20
pubmed: 11288928
J Neurooncol. 2018 Sep;139(3):661-670
pubmed: 29845423
Horm Metab Res. 2013 Sep;45(10):754-8
pubmed: 23828125
PLoS One. 2012;7(3):e32487
pubmed: 22396771
J Biol Chem. 1981 Sep 10;256(17):9167-73
pubmed: 7021557
Eur Rev Med Pharmacol Sci. 2016 Oct;20(19):4041-4047
pubmed: 27775795
Bull World Health Organ. 1966;34(3):379-93
pubmed: 5296398
Thyroid Res. 2012 Dec 27;5(1):25
pubmed: 23270549
PLoS One. 2016 Jul 28;11(7):e0160032
pubmed: 27467818
J Epidemiol Community Health. 2015 Mar;69(3):294-300
pubmed: 25271248
Blood. 1994 Dec 1;84(11):3613-36
pubmed: 7949118
J Clin Endocrinol Metab. 2015 Nov;100(11):4037-47
pubmed: 26305620
ACG Case Rep J. 2022 Aug 31;9(8):e00845
pubmed: 36061252
Scand J Gastroenterol. 2021 Feb;56(2):171-176
pubmed: 33327797
Rev Endocr Metab Disord. 2022 Jun;23(3):431-447
pubmed: 34529221
Mol Cell Endocrinol. 2017 Dec 15;458:6-15
pubmed: 28153798
Mol Cell. 2014 Jul 17;55(2):253-63
pubmed: 24882210
Ann Med. 2018 Feb;50(1):68-73
pubmed: 28985689
FEBS Lett. 1985 Jul 1;186(1):107-10
pubmed: 3924659
Redox Biol. 2017 Apr;11:701-707
pubmed: 28187322
Sci Total Environ. 2007 Apr 15;376(1-3):160-77
pubmed: 17336368
J Vasc Res. 2007;44(4):253-63
pubmed: 17361089
J Clin Med. 2022 Oct 12;11(20):
pubmed: 36294348
Endocrinology. 1984 Jul;115(1):392-8
pubmed: 6329661
Eur J Clin Chem Clin Biochem. 1996 May;34(5):431-8
pubmed: 8790979
Endocr Relat Cancer. 2011 Dec 01;18(6):773-82
pubmed: 22002574
Eur Rev Med Pharmacol Sci. 2020 Dec;24(23):12500-12509
pubmed: 33336769
Oxid Med Cell Longev. 2021 Apr 29;2021:5529256
pubmed: 34007401
Thyroid. 2016 Apr;26(4):504-11
pubmed: 26854840
Toxicol Res (Camb). 2018 Mar 6;7(3):347-357
pubmed: 30090586
Mediators Inflamm. 2016;2016:6757154
pubmed: 27051079
Arch Biochem Biophys. 2006 Jan 15;445(2):269-77
pubmed: 16098474
Int J Mol Sci. 2020 Oct 10;21(20):
pubmed: 33050491
Mol Aspects Med. 2009 Feb-Apr;30(1-2):1-12
pubmed: 18796312
J Diabetes Res. 2016;2016:1401829
pubmed: 27123460
PeerJ. 2017 Jun 1;5:e3365
pubmed: 28584708
Eur J Biochem. 1981 Jun;117(1):103-9
pubmed: 7262079
Blood. 2020 Sep 10;136(11):1225-1240
pubmed: 32702756
Diabetes Care. 2011 Jan;34(1):162-7
pubmed: 20929994
Eur J Immunol. 2006 May;36(5):1199-209
pubmed: 16598818
J Clin Endocrinol Metab. 2022 Aug 18;107(9):e3603-e3611
pubmed: 35789269
Am J Clin Nutr. 1993 Feb;57(2 Suppl):236S-239S
pubmed: 8427195